Get the Stockscreener App
0.6869
4.06%
0.0268
Karyopharm Therapeutics Inc stock is traded at $0.6869, with a volume of 835.80K.
It is up +4.06% in the last 24 hours and up +8.17% over the past month.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
See More
Previous Close:
$0.6601
Open:
$0.66
24h Volume:
835.80K
Relative Volume:
0.90
Market Cap:
$86.68M
Revenue:
$140.46M
Net Income/Loss:
$-146.34M
P/E Ratio:
-0.5409
EPS:
-1.27
Net Cash Flow:
$-117.73M
1W Performance:
+8.48%
1M Performance:
+8.17%
6M Performance:
-22.82%
1Y Performance:
-10.33%
1-Day Range:
$0.651
$0.72
1-Week Range:
$0.6126
$0.72
52-Week Range:
$0.5809
$1.95
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
Name
Karyopharm Therapeutics Inc
Sector
Industry
Phone
617-658-0600
Address
85 WELLS AVENUE, NEWTON, MA
Compare KPTI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
0.6869 | 86.68M | 140.46M | -146.34M | -117.73M | -1.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-19-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-09-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-06-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-06-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-02-20 | Initiated | Morgan Stanley | Overweight |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-17-20 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-23-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-05-19 | Reiterated | H.C. Wainwright | Buy |
| Jul-05-19 | Reiterated | Robert W. Baird | Outperform |
| Mar-01-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-28-19 | Reiterated | BofA/Merrill | Underperform |
| Feb-27-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jan-03-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Dec-03-18 | Initiated | B. Riley FBR | Buy |
| Nov-09-18 | Upgrade | Wedbush | Neutral → Outperform |
| May-24-18 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-02-18 | Resumed | Leerink Partners | Outperform |
| Nov-15-17 | Resumed | H.C. Wainwright | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-08-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-30-16 | Upgrade | Jefferies | Hold → Buy |
| Aug-18-16 | Initiated | H.C. Wainwright | Buy |
| Jun-28-16 | Initiated | Robert W. Baird | Outperform |
View All
Karyopharm Therapeutics Inc Stock (KPTI) Latest News
Karyopharm Therapeutics’ (KPTI) “Buy” Rating Reiterated at HC Wainwright - Defense World
What is HC Wainwright’s Estimate for KPTI FY2024 Earnings? - Defense World
What is HC Wainwright's Forecast for KPTI FY2024 Earnings? - MarketBeat
HC Wainwright Reiterates Buy Rating for Karyopharm Therapeutics (NASDAQ:KPTI) - MarketBeat
Karyopharm Therapeutics' SWOT analysis: oncology firm's stock faces pivotal year - Investing.com India
Karyopharm Therapeutics’ SWOT analysis: oncology firm’s stock faces pivotal year - Investing.com Nigeria
Jane Street Group LLC Sells 1,345,226 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - MarketBeat
Jane Street Group LLC Has $170,000 Stake in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Defense World
KPTIKaryopharm Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
Karyopharm announces preliminary 2024 revenue - MSN
Karyopharm Reports $145M Revenue for 2024, Advances Phase 3 Myelofibrosis Trial - StockTitan
Why Karyopharm Therapeutics (KPTI) Is Among the Best Penny Stocks to Invest In According to Media? - MSN
Geode Capital Management LLC Has $1.13 Million Stake in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Defense World
Barclays PLC Has $79,000 Stock Holdings in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Defense World
Barclays PLC Sells 777,507 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - MarketBeat
Karyopharm CEO sells common stock for $3,175 By Investing.com - Investing.com Canada
12 Best Penny Stocks to Invest in According to the Media - Insider Monkey
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Position Reduced by State Street Corp - Defense World
Karyopharm appoints new CFO effective January 3 By Investing.com - Investing.com Australia
Karyopharm appoints new CFO effective January 3 - Investing.com India
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Karyopharm Appoints Lori Macomber as Chief Financial Officer - citybiz
Karyopharm Welcomes New Chief Financial Officer - Contract Pharma
Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer, Effective January 3, 2025 - Marketscreener.com
Karyopharm appoints new CFO to bolster financial strategy - Investing.com
Karyopharm Therapeutics names Lori Macomber as CFO - MSN
Karyopharm Appoints Lori Macomber as New CFO - TipRanks
Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer - Citizentribune
Karyopharm Therapeutics (NASDAQ:KPTI) Shares Pass Below 50 Day Moving AverageWhat's Next? - MarketBeat
KPTI stock touches 52-week low at $0.59 amid market challenges - Investing.com Canada
Karyopharm Therapeutics (STU:25K) Revenue per Share : €1.07 (TTM As of Sep. 2024) - GuruFocus.com
Lacklustre Performance Is Driving Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) 27% Price Drop - Simply Wall St
Fmr LLC Buys 76,510 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Defense World
KPTI stock touches 52-week low at $0.65 amid market challenges By Investing.com - Investing.com South Africa
KPTI stock touches 52-week low at $0.65 amid market challenges - Investing.com Canada
Karyopharm Therapeutics Inc.'s SWOT analysis: oncology firm's stock faces pivotal trials - Investing.com
Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024 - The Eastern Progress Online
Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications - Kilgore News Herald
Karyopharm Appoints Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications - citybiz
Karyopharm Strengthens Leadership Team with Key IR Appointment Ahead of 2025 Pipeline Milestones - StockTitan
Karyopharm Therapeutics Inc Stock (KPTI) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):